Assessment of the relationship of lipid metabolism and pulmonary hypertension in the initial periods of myocardial infarction in men under 60 years old
https://doi.org/10.25789/YMJ.2024.85.02
Abstract
Pulmonary hypertension (PH) is an understudied but significant complication of myocardial infarction (MI). Currently, there are no diagnostic algorithms that can predict the development of PH in the setting of myocardial infarction, which requires the development of prediction models based on the results of routine examination, for example, lipid profile. The purpose of the research was to study the parameters of lipid metabolism in men with PH that developed against the background of MI and their impact on the risk of developing PH. The results of examination of men aged 32-60 years with verified MI were studied. According to the level of mean pulmonary artery pressure (MPAP) determined by echocardiography, patients were divided into two groups: the study group (with a MPAP level of more than 20 mm Hg at the end of the third week of MI) and the comparison group (with a normal MPAP level at the end of the third week of MI). The studied indicators were compared based on the Mann-Whitney, Wilcoxon, and Chi-square tests; correlations were performed using the Spearman method. It was found that patients in the study group had lower levels of the atherogenic coefficient (AC) and the total cholesterol/high-density lipoprotein (TC/HDL) index at the end of the third week of MI. Levels of triglycerides (TG) < 1.3 mmol/l and very low density lipoprotein (VLDL) ≥ 1.2 mmol/l, TC/HDL indices < 6.0 and LDL/HDL < 3.2 in the first 48 hours, LDL <2.4 mmol/l, AC value <5.0, TC/HDL indices <6.0 and LDL/HDL <3.2 at the end of the third week of MI influence the risk of developing PH in the subacute period of MI. Correlations have also been established between the level of MPAP and lipid profile parameters. It is advisable to use the obtained results when developing a model for predicting the development of PH against the background of MI.
About the Authors
A. N. Menshikova
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
MENSHIKOVA Alexandra Nikolaevna – adjunct of the Department of Hospital Therapy
A. V. Sotnikov
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
SOTNIKOV Alexey Vladimirovich – Doctor of Medical Sciences, Docent, Professor of the Department of Hospital Therapy
A. V. Gordienko
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
GORDIENKO Alexander Voleslavovich – Doctor of Medi- cal Sciences, Professor, Associate Professor of the Department of Hospital Therapy
D. V. Nosovich
S.M. Kirov Military Medical Academy
Russian Federation
Russian Federation
NOSOVICH Dmitry Vladimirovich – Candidate of Medical Sciences, Senior Lecturer at the Department of Hospital Therapy
References
1. Avdeev S.N. [et al.] Legochnaya gipertenziya, v tom chisle khronicheskaya tromboembolicheskaya legochnaya gipertenziya. Klinicheskie rekomendatsii 2020 [Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Clinical guidelines 2020]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology. 2021; 12:198-267 (In Russ.).] doi:10.15829/1560-4071-2021-4683.
2. Litovskiy I.A., Gordienko A.V., Sotnikov A.V. Dostatochno li obosnovany tseli, k kotorym my stremimsya? [Are the goals we strive for sufficiently justified?] Klinicheskaya farmakologiya i terapiya. [Clinical pharmacology and therapy. 2019; 4(28):10-23 (In Russ.).] DOI 10.32756/0869-5490-2019-4-10-23.
3. Yezhov M.V. [et al.] Narusheniya lipidnogo obmena. Klinicheskie rekomendatsii 2023 [Disorders of lipid metabolism. Clinical guidelines 2023]. Russian Journal of Cardiology [Rossiyskiy kardiologicheskiy zhurnal. 2023; 28 (5): 250-297 (In Russ.).] doi 10.15829/1560-4071-2023-547
4. Oynotkinova O.Sh., Nikonov E.L., Kryukov E.V. Evolyutsiya dislipidemii: ot etiologicheskikh mekhanizmov k novym mishenyam personalizirovannoy profilakticheskoy nutritsevticheskoy terapii krasnym drozhzhevym risom [Evolution of dyslipidemia: from etiological mechanisms to new targets for personalized preventive nutraceutical therapy with red yeast rice]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and prevention. 2019; 6(18): 88-98 (In Russ.).] doi.org/10.15829/1728-8800-2019-6-88-98.
5. Averkov O.V. [et al.]. Ostryy infarkt miokarda s podemom segmenta ST elektrokardiogrammy. Klinicheskie rekomendatsii 2020 [Acute myocardial infarction with ST segment elevation of the electrocardiogram. Clinical guidelines 2020]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology. 2020; 11: 251-310 (In Russ.).] doi:10.15829/1560-4071-2020-4103.
6. Otto K.M. Klinicheskaya ekhokardiografiya: prakticheskoe rukovodstvo [Clinical echocardiography: a practical guide]. Edited by Galagudzi M.M., Domnitskaya T.M., Zelenikina M.M., Kulagina T.Yu., Nikiforov V.S., Sandrikov V.A. M.: Logosphere, 2019. 1352 p. (In Russ.).] ISBN 9785-98657-064-8.
7. Gordienko A.V. [et al.]. Faktory riska razvitiya ostrogo povrezhdeniya pochek pri infarkte miokarda u muzhchin molodogo i srednego vozrasta, stradayushchikh podagroy [Risk factors for the development of acute kidney injury during myocardial infarction in young and middle-aged men suffering from gout]. Mediko-farmatsevtich- eskiy zhurnal Puls [Medical and pharmaceutical journal Pulse. 2022; 24 (9):29-36 (In Russ.).] DOI 10.26787/nydha-2686-6838-2022-24-9-29-36.
8. Galderisi M. [et al.]. 2016–2018 EACVI Scientific Documents Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular I. Eur Heart J Cardiovasc Imaging. 2017; 18(12):1301- 1310. doi: 10.1093/ehjci/jex244.
9. Diaconu R. [et al.] Apolipoprotein E4 Is Associated with Right Ventricular Dysfunction in Dilated Cardiomyopathy-An Animal and In-Human Comparative Study. Int J Mol Sci. 2021; 22(18): 9688. URL: https://www.mdpi.com/1422-0067/22/18/9688 (Reference date: 07.06.2023). doi: 10.3390/ijms22189688.
10. Boratkó A., Csortos C. TIMAP, the versatile protein phosphatase 1 regulator in endothelial cells //IUBMB Life. 2017; 69(12): 918-928. doi: 10.1002/ ub.1695.
11. Gorelova A., Berman M., Al Ghouleh I. Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension. Antioxid Redox Signal. 2021. Ryter S.W., Bhatia D., Choi M.E. Autophagy: A Lysosome-Dependent Process with Implications in Cellular Redox Homeostasis and Human Disease. Antioxid Redox Signal. 2019 Jan 1;30(1):138-159. doi: 10.1089/ars.2018.7518. Epub 2018 Mar 28. PMID: 29463101; PMCID: PMC6251060. 34(12). P. 891-914. doi: 10.1089/ars.2020.8169.
12. Virani S.S. [et al.]. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circu-lation. 2021; 143(8): 254-743. doi: 10.1161/CIR.0000000000000950.
13. Ye W. [et al.]. Heart-lung crosstalk in pulmonary arterial hypertension following myocardial infarction (Review). Int J Mol Med. 2020; 46(3): 913-924. doi: 10.3892/ijmm.2020.4650.
14. Johnson J.L. Elucidating the contributory role of microRNA to cardiovascular diseases (a review). Vascul. Pharmacol. 2019; 114:31-48. doi: 10.1016/j.vph.2018.10.010.
15. Kitabatake A., Iuone M., Asao M. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983; 68(2):302-309.
16. LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis / X. Shi [et al.] // Clin Transl Med. 2022. V. 12(1). е711. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792399/ (дата обращения: 07.06.2023). Текст: электронный. doi: 10.1002 / ctm2.711.
17. Çetin M. [et al.]. Left atrial volume index and pulmonary arterial pressure predicted MACE among patients with STEMI during 8-year follow-up: experience from a tertiary center. Herz. 2021. V. 46(4). P. 367-374. doi: 10.1007/s00059020-04966-4.
18. Brittain E.L. [et al.]. Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2020; 9(22): e018349. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763730/ (Date of reference 03.07.2023). doi: 10.1161/JAHA.120.018349.
19. Sharma S. [et al.] Role of oxidized lipids in pulmonary arterial hypertension. Pulm Circ. 2016; 6(3): 261-273. doi: 10.1086/687293.
20. Ryter S.W., Bhatia D., Choi M.E. Autophagy: A Lysosome-Dependent Process with Implications in Cellular Redox Homeostasis and Human Disease. Antioxid Redox Signal. 2019; 30(1): 138-159. doi: 10.1089/ars.2018.7518.
21. Vuorio A., Lassila R., Kovanen P.T. Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism //Frontiers in cardiovascular medicine. 2021. V. 8. 711923. URL: https://www.frontiersin.org/articles/10.3389/fcvm.2021.711923/full. (Date of reference: 08.06.2023). doi: 10.3389/fcvm.2021.711923.
22. Xu J., Chen G., Yang Y. Exosomes: A Rising Star in Falling Hearts //Front. Physiol. 2017; 8: 494. doi: 10.3389/fphys.2017.00494.
Review
For citations:
Menshikova A.N., Sotnikov A.V., Gordienko A.V., Nosovich D.V. Assessment of the relationship of lipid metabolism and pulmonary hypertension in the initial periods of myocardial infarction in men under 60 years old. Yakut Medical Journal. 2024;(1):8-12. https://doi.org/10.25789/YMJ.2024.85.02
Views:
31
Email this article 